Biohaven’s epilepsy drug hit with FDA clinical hold
Pivotal study enrolment has been paused while Biohaven characterises a metabolite of opakalim and its safety in humans.
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo